| The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak HA Rothan, SN Byrareddy Journal of autoimmunity 109, 102433, 2020 | 8056 | 2020 |
| Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase … K Balasubramanyam, RA Varier, M Altaf, V Swaminathan, NB Siddappa, ... Journal of Biological Chemistry 279 (49), 51163-51171, 2004 | 974 | 2004 |
| Impact of social determinants of health on the emerging COVID-19 pandemic in the United States S Singu, A Acharya, K Challagundla, SN Byrareddy Frontiers in public health 8, 564623, 2020 | 369 | 2020 |
| The 2022 outbreak and the pathobiology of the monkeypox virus N Kumar, A Acharya, HE Gendelman, SN Byrareddy Journal of autoimmunity 131, 102855, 2022 | 368 | 2022 |
| Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses SR Kannan, AN Spratt, AR Cohen, SH Naqvi, HS Chand, TP Quinn, ... Journal of autoimmunity 124, 102715, 2021 | 261 | 2021 |
| Sustained virologic control in SIV+ macaques after antiretroviral and α4β7 antibody therapy SN Byrareddy, J Arthos, C Cicala, F Villinger, KT Ortiz, D Little, N Sidell, ... Science 354 (6309), 197-202, 2016 | 249 | 2016 |
| Omicron SARS-CoV-2 variant: Unique features and their impact on pre-existing antibodies SR Kannan, AN Spratt, K Sharma, HS Chand, SN Byrareddy, K Singh Journal of autoimmunity 126, 102779, 2022 | 231 | 2022 |
| Specific inhibition of p300-HAT alters global gene expression and represses HIV replication K Mantelingu, BAA Reddy, V Swaminathan, AH Kishore, NB Siddappa, ... Chemistry & biology 14 (6), 645-657, 2007 | 225 | 2007 |
| Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine U Ranga, R Shankarappa, NB Siddappa, L Ramakrishna, R Nagendran, ... Journal of virology 78 (5), 2586-2590, 2004 | 207 | 2004 |
| Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy–treated macaques PJ Santangelo, KA Rogers, C Zurla, EL Blanchard, S Gumber, K Strait, ... Nature methods 12 (5), 427-432, 2015 | 174 | 2015 |
| Clade‐specific differences in neurotoxicity of human immunodeficiency virus‐1 B and C Tat of human neurons: significance of dicysteine C30C31 motif M Mishra, S Vetrivel, NB Siddappa, U Ranga, P Seth Annals of neurology 63 (3), 366-376, 2008 | 160 | 2008 |
| Targeting α4β7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection SN Byrareddy, B Kallam, J Arthos, C Cicala, F Nawaz, J Hiatt, EN Kersh, ... Nature medicine 20 (12), 1397-1400, 2014 | 156 | 2014 |
| The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic V Namasivayam, M Vanangamudi, VG Kramer, S Kurup, P Zhan, X Liu, ... Journal of medicinal chemistry 62 (10), 4851-4883, 2018 | 140 | 2018 |
| Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission JD Watkins, AM Sholukh, MM Mukhtar, NB Siddappa, SK Lakhashe, ... Aids 27 (9), F13-F20, 2013 | 129 | 2013 |
| HIV-1 clade-specific differences in the induction of neuropathogenesis VR Rao, AR Sas, EA Eugenin, NB Siddappa, H Bimonte-Nelson, ... Journal of neuroscience 28 (40), 10010-10016, 2008 | 125 | 2008 |
| Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques L Micci, ES Ryan, R Fromentin, SE Bosinger, JL Harper, T He, S Paganini, ... The Journal of clinical investigation 125 (12), 4497-4513, 2015 | 115 | 2015 |
| Mental health issues during and after COVID-19 vaccine era K Pandey, M Thurman, SD Johnson, A Acharya, M Johnston, EA Klug, ... Brain research bulletin 176, 161-173, 2021 | 102 | 2021 |
| An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV JD Watkins, NB Siddappa, SK Lakhashe, M Humbert, A Sholukh, ... PloS one 6 (3), e18207, 2011 | 101 | 2011 |
| SARS-CoV-2 infection leads to neurological dysfunction A Acharya, BD Kevadiya, HE Gendelman, SN Byrareddy Journal of Neuroimmune Pharmacology 15, 167-173, 2020 | 95 | 2020 |
| COVID-19 and cancer comorbidity: therapeutic opportunities and challenges AS Pathania, P Prathipati, BAA Abdul, S Chava, SS Katta, SC Gupta, ... Theranostics 11 (2), 731, 2021 | 89 | 2021 |
Muhammad M MukhtarResaerch fellow, Dana-Farber Cancer Institute, Harvard Medical SchoolVerified email at dfci.harvard.edu
